MedTrace Logo

Intravenous Nalbuphine for Prevention of Intrathecal Morphine-induced Nausea and Vomiting in Patients Undergoing Cesarean Section: A Double-blind, Randomized Controlled Trial.

NCT06837129 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-01-28

No results posted yet for this study

Summary

We study efficacy of iv nalbuphine in prevention of intrathecal morphine-induced nausea and vomiting in patients undergoing cesarean section.

Conditions

  • Intrathecal Morphine
  • Caesarean Section
  • Postoperative Nausea and Vomiting
  • Neuraxial Opioid

Interventions

DRUG

A single dose of 4 mg iv nalbuphine

prevention of nausea vomiting

Sponsors & Collaborators

  • Thammasat University

    lead OTHER

Principal Investigators

  • Assist. Prof. Dr. Preeyaphan Arunakul, M.D., FRCAT · Thammasat University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-15
Primary Completion
2025-02-15
Completion
2025-02-20

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06837129 on ClinicalTrials.gov